Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Endocrine Ips PLLC

Neither a doctor nor a teaching hospital

Research payments

$6,865,154

249 payments

Through program year 2025, Endocrine Ips PLLC is reported as receiving $6,865,154 in research payments, across 249 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,769,744 32
2024 Research $1,899,903 30
2023 Research $928,020 14
2022 Research $584,460 22
2021 Research $850,062 43
2020 Research $533,177 66
2019 Research $299,786 42

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $5,434,148 88 payments
  2. AstraZeneca Pharmaceuticals LP $308,517 11 payments
  3. AstraZeneca UK Limited $251,537 4 payments
  4. Sanofi US Services Inc. $239,383 21 payments
  5. Pfizer Inc. $236,248 30 payments
  6. AbbVie, Inc. $228,108 35 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $124,582 48 payments
  8. Corcept Therapeutics $21,870 9 payments
  9. Janssen Research & Development, LLC $16,262 2 payments
  10. Lexicon Pharmaceuticals, Inc. $4,500 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Phase 2 Study With Combination of Vemurafenib With Cobimetinib in B-Raf V600e/K Mutated Melanoma Patients to Normalize LDH and Optimize Nivolumab and Ipilimumab Therapy $639,595 4 payments
  2. A Phase 3B Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide 2.4 MG in Adults Who Have Obesity Or Overweight With Weight-Related Comorbidities (Surmount-5) $436,107 2 payments
  3. A Phase 2a Randomized Double blind Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease $397,629 6 payments
  4. A Phase 3B, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide 2.4 MG in Adults Who Have Obesity Or Overweight With Weight-Related Comorbidities (Surmount-5) $375,526 2 payments
  5. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $340,728 4 payments
  6. A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With Ly3841136 and Tirzepatide, Alone Or in Combination, in Adult Participants With Obesity Or Overweight With Type 2 Diabetes $302,328 4 payments
  7. A Phase 2 Study of Once-Weekly Ly3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes $299,509 4 payments
  8. A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With Ly3841136 Compared With Placebo in Adult Participants With Obesity Or Overweight $279,008 4 payments
  9. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index Greater Than 27 KG M2 and Atherosclerotic Cardiovascular Disease and Or Chronic Kidney Disease $275,806 4 payments
  10. Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity Or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-2) $249,225 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record